Filing Flows › Jazz Pharmaceuticals (JAZZ) › Guidance history
Jazz Pharmaceuticals (JAZZ) guidance history: what it guided and what it reported
Jazz Pharmaceuticals gave guidance in 13 earnings releases on file since Feb 28, 2024. Of 3 guided periods since reported, it met or beat its own guidance 3 times (100%). Revenue: 2 of 2, on average +0.7% against the guided midpoint. Its releases raised guidance 5 times and lowered it twice.
Revenue
Met or beat 2 of 2 periods (0 above, 2 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $4.2B–$4.5B (Feb 24, 2026) → raised $4.6B–$4.8B (Aug 3, 2026) → raised $4.8B–$4.8B (Nov 2, 2026) | — | to be reported | — |
| FY2025 | $4.2B–$4.4B (Feb 25, 2025) → reaffirmed $4.2B–$4.4B (May 6, 2025) → lowered $4.2B–$4.3B (Aug 5, 2025) → reaffirmed $4.2B–$4.3B (Nov 5, 2025) | $4.3B | within the range | +1.0% |
| FY2024 | $4.0B–$4.2B (Feb 28, 2024) → reaffirmed $4.0B–$4.2B (May 1, 2024) → lowered $4.0B–$4.1B (Jul 31, 2024) → reaffirmed $4.0B–$4.1B (Nov 6, 2024) | $4.1B | within the range | +0.5% |
GAAP gross margin
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | 88.0% (Feb 25, 2025) | — | — | — |
| FY2024 | 89.0% (Feb 28, 2024) → reaffirmed 89.0% (May 1, 2024) | — | — | — |
Gross margin
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 89.0%–90.0% (Aug 3, 2026) → reaffirmed 89.0%–90.0% (Nov 2, 2026) | — | to be reported | — |
| FY2025 | 88.0% (May 6, 2025) → reaffirmed 88.0% (Aug 5, 2025) → reaffirmed 88.0% (Nov 5, 2025) | — | — | — |
| FY2024 | 89.0% (Jul 31, 2024) → reaffirmed 89.0% (Nov 6, 2024) | — | — | — |
Adjusted gross margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | 92.0% (Feb 25, 2025) | — | — | — |
| FY2024 | 93.0% (Feb 28, 2024) → reaffirmed 93.0% (May 1, 2024) | — | — | — |
GAAP net income
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $560M–$720M (Feb 25, 2025) | — | — | — |
| FY2024 | $385M–$530M (Jul 31, 2024) | $560M | above the range | +22.4% |
Net income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | $430M–$550M (Nov 6, 2024) | — | — | — |
The latest quarter
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
Questions
Does Jazz Pharmaceuticals beat its guidance?
Jazz Pharmaceuticals gave guidance in 13 earnings releases on file since Feb 28, 2024. Of 3 guided periods since reported, it met or beat its own guidance 3 times (100%). Revenue: 2 of 2, on average +0.7% against the guided midpoint.
How often does Jazz Pharmaceuticals raise guidance?
Its earnings releases raised guidance 5 times and lowered it twice since Feb 28, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.